| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,315 |
4,983 |
$843K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,306 |
1,866 |
$404K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,396 |
1,137 |
$121K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
370 |
259 |
$51K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,467 |
1,340 |
$33K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,052 |
4,014 |
$27K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
972 |
736 |
$21K |
| 71046 |
Radiologic examination, chest; 2 views |
445 |
374 |
$20K |
| 80053 |
Comprehensive metabolic panel |
3,452 |
2,895 |
$19K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
485 |
424 |
$17K |
| 70450 |
Computed tomography, head or brain; without contrast material |
86 |
75 |
$15K |
| 36415 |
Collection of venous blood by venipuncture |
1,010 |
945 |
$10K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,027 |
822 |
$10K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
118 |
104 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
285 |
247 |
$7K |
| 84484 |
|
1,098 |
862 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
106 |
45 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
89 |
78 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
97 |
93 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
106 |
45 |
$1K |
| 82550 |
|
265 |
218 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
305 |
218 |
$908.06 |
| 83880 |
|
96 |
80 |
$756.24 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
52 |
37 |
$584.85 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
49 |
40 |
$555.37 |
| 99220 |
|
14 |
13 |
$353.22 |
| 71045 |
Radiologic examination, chest; single view |
12 |
12 |
$317.08 |
| 83605 |
|
45 |
37 |
$315.36 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
29 |
28 |
$292.14 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
55 |
49 |
$273.45 |
| 99217 |
|
19 |
18 |
$264.26 |
| 81001 |
|
190 |
173 |
$258.45 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
32 |
24 |
$187.60 |
| 83735 |
|
31 |
26 |
$151.74 |
| 83690 |
|
60 |
51 |
$130.05 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
27 |
14 |
$80.01 |
| 87070 |
|
13 |
12 |
$32.34 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
32 |
28 |
$24.25 |
| J3490 |
Unclassified drugs |
23 |
15 |
$0.00 |
| 3008F |
|
54 |
42 |
$0.00 |
| 82150 |
|
14 |
13 |
$0.00 |
| 1160F |
|
91 |
72 |
$0.00 |
| 1159F |
|
55 |
43 |
$0.00 |